Grant List
Represents Grant table in the DB
GET /v1/grants?page%5Bnumber%5D=1385&sort=principal_investigator
{ "links": { "first": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1&sort=principal_investigator", "last": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1442&sort=principal_investigator", "next": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1386&sort=principal_investigator", "prev": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1384&sort=principal_investigator" }, "data": [ { "type": "Grant", "id": "15249", "attributes": { "award_id": "1K01AT012650-01A1", "title": "Culturally tailoring a mindfulness meditation mobile app to reduce psychological distress in African American adults", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Center for Complementary and Integrative Health (NCCIH)" ], "program_reference_codes": [], "program_officials": [ { "id": 23034, "first_name": "Peter Daniel", "last_name": "Murray", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2024-08-09", "end_date": "2029-07-31", "award_amount": 151672, "principal_investigator": { "id": 31836, "first_name": "Jennifer Logan", "last_name": "Green", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 775, "ror": "https://ror.org/0264fdx42", "name": "San Diego State University", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true }, "abstract": "This K01 is a mixed methods research project in collaboration with an industry partner (i.e., Healthy Minds Innovations) and will be conducted across three aims during a 5-year comprehensive training program. In this innovative proposal, the candidate has identified a mentorship team and training goals to facilitate their transition to an independent research career focused on achieving health equity and advancing mind-body research by delivering culturally tailored digital health interventions to improve mental health and well-being in underserved populations. Background: African American (AA) adults are 20% more likely to report serious psychological distress (e.g., stress, anxiety, depression) compared to white adults. Racial discrimination, a significant source of stress in AA adults, increases psychological distress. AA adults lack access to quality mental health care and the compounding impact of the COVID-19 pandemic may further exacerbate mental health disparities. Reducing psychological distress and increasing access to mental health care for AA adults is a public health emergency. Commercially available mindfulness meditation mobile apps may be an effective and efficient solution because they improve psychological distress, are highly scalable and can increase access to care. However, most are not culturally tailored (i.e., include groups’ unique experiences, values, and beliefs). Culturally tailoring mindfulness meditation apps can enhance engagement and efficacy in racial/ethnic minority populations. Specific aims and research design: The goal of Aim 1 is to inform the development of an app prototype via focus groups (N=4, 5 participants each) in AA adults (half meditators, half non-meditators). The goal of Aim 2 is to culturally tailor a commercial mindfulness meditation app (Healthy Minds Program app) through a User-Centered Design (UCD) workshop. AA adults (N=8) will attend a virtual half-day UCD workshop where they will co-design an app prototype. After the prototype is built, participants will test it for 1 week and complete an exit interview to refine the app. Aim 3 will determine the feasibility of the culturally tailored prototype app following predetermined benchmarks. AA adults with elevated stress (N=72) will be randomized to use HMP or a health education app (The Wellness App) for 8 weeks. Psychological distress, race-related stress, mindfulness, and self- compassion will be measured at pre-, mid-, and post-intervention. Acceptability (ability to recruit, satisfaction, continued use, appropriateness) will be assessed with a post-intervention satisfaction survey. Demand (adherence to treatment) will be measured by objective app usage data (sessions/minutes completed) and attrition rate. Mentoring and training: A team of expert mentors and advisors (Vranceanu, Burnett-Zeigler, Gallo, and Roesch) will oversee the progress of this study and contribute to mentoring the candidate across 4 training goals aimed to develop expertise in: 1) mental health disparities, 2) cultural tailoring methods, 3) digital clinical trials, and 4) qualitative and mixed methods research and advanced statistics. This proposal aligns with NCCIH’s funding priorities including the development of feasible mobile health (mHealth) mind- body interventions and reducing health disparities. Impact: Collectively, this career development award will serve as a strong foundation toward the candidate’s independent research career and provides an innovative solution to improve access to mental health care for AA adults.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "15250", "attributes": { "award_id": "1R01MD019798-01", "title": "School-Located Vaccination to Reduce Inequities in Vaccination Uptake Among Historically Excluded Populations in Colorado", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute on Minority Health and Health Disparities (NIMHD)" ], "program_reference_codes": [], "program_officials": [ { "id": 6025, "first_name": "Crystal", "last_name": "Barksdale", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2024-08-12", "end_date": "2027-02-28", "award_amount": 582465, "principal_investigator": { "id": 31837, "first_name": "Laura Johnson", "last_name": "Faherty", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [ { "id": 31838, "first_name": "Ashley", "last_name": "Gromis", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 515, "ror": "https://ror.org/00f2z7n96", "name": "RAND Corporation", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true }, "abstract": "Health disparity populations are more likely to face barriers to immunization in traditional medical settings. Specifically, people from minoritized racial/ethnic groups, residents of underserved rural areas, and households with less advantaged socio-economic status are more likely to lack a primary care medical home, report logistical challenges accessing medical offices (e.g., lack of transportation, clinic hours, long wait times), and live in areas with poor access to primary care. Prior to the COVID-19 pandemic, school-located vaccination (SLV) had been successfully used for routine and pandemic (H1N1) vaccines to overcome some of these access barriers. SLV can occur through School-Based Health Centers (SBHCs) or School-Located Vaccine Clinics (SLVCs). SLVCs are time-limited events focused on the mass delivery of one or more vaccines. They can be led by a school nurse, coordinated through an SBHC, if available, or conducted in partnership with local health systems or health departments. As only 13% of public school students in the United States had access to an SBHC in the 2016-17 school year, SLVCs play an important role in extending the reach of SLV. Recently, schools gained substantial experience with SLVCs due to the urgency of the pediatric COVID-19 vaccine roll-out. Because most SBHCs are located in urban, low-income, and racially/ethnically minoritized communities and SLVCs typically provide vaccines free of cost to all students regardless of insurance status, they are often assumed to improve health equity. However, there have been no systematic investigations of the full scope of SLV models (SBHCs, SLVCs independent of an SBHC, and SLVCs run by SBHCs) to determine whether locating vaccination services in schools increases immunization rates in health disparity populations. To fill this critical gap, this study will apply quasi-experimental methods, microsimulation modeling, and a modified positive deviance approach grounded in implementation science to examine the impact of the three models of SLV (SBHCs, SLVCs, and both) on routine, influenza, and COVID- 19 vaccination rates among school-aged children in Colorado, overall and for health disparity populations. We aim to: (1) Describe SLV models (SBHCs, SLVCs, and both) in Colorado from 2018-2024, the local context in which they were implemented, and how model and school characteristics changed over time; (2) Estimate causal impacts of SLV models on routine, influenza, and COVID-19 vaccine uptake among school-aged children (5-17 years) from 2018-2024; (3) Simulate potential local- and state-level impacts of SLVCs on routine, influenza, and COVID-19 vaccine coverage among all students in Colorado and members of health disparity populations; and (4) Qualitatively investigate contextual barriers to and facilitators of recent SLV implementation in Colorado. Study findings will be immediately actionable for SLV implementers and policymakers seeking to reduce vaccination disparities among school-aged children and adolescents.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "15332", "attributes": { "award_id": "1R01MH138475-01", "title": "Impacts of Telehealth Policies on Inequities in Perinatal Behavioral Health Care Access and Outcomes", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)" ], "program_reference_codes": [], "program_officials": [ { "id": 6350, "first_name": "Jennifer", "last_name": "Humensky", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2024-09-10", "end_date": "2028-06-30", "award_amount": 677945, "principal_investigator": { "id": 31837, "first_name": "Laura Johnson", "last_name": "Faherty", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [ { "id": 31929, "first_name": "Rachel Keller", "last_name": "Landis", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 515, "ror": "https://ror.org/00f2z7n96", "name": "RAND Corporation", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true }, "abstract": "Project Abstract: Suicide is now the leading cause of death during the perinatal period, and nearly a quarter of maternal deaths are attributable to behavioral health (BH) conditions. As with maternal mortality and morbidity overall, poor perinatal BH outcomes disproportionately affect historically marginalized communities of color. Despite the prevalence and life-threatening nature of perinatal BH conditions, only 11% of individuals with these conditions during pregnancy or postpartum receive needed care, and individuals from marginalized and under-resourced populations are less likely to be screened or treated for BH conditions. Telehealth has enormous potential to address the maternal morbidity and mortality crisis by improving access to perinatal BH care. It has been shown to increase health care access and reduce missed appointments for BH care, particularly among individuals from underserved communities. Research overwhelmingly finds comparable efficacy between in- person and telebehavioral health (TBH) care. Finally, telehealth can help overcome particularly salient barriers for pregnant and postpartum people. Few studies have examined TBH in the perinatal period, but evidence suggests that TBH services for pregnant and postpartum people provide equivalent benefit to those delivered in-person. Importantly, pregnant and postpartum individuals from historically marginalized populations, (e.g., Medicaid-insured; those living in rural areas; those with disabilities; and members of racial and ethnic minority groups), face additional health care barriers, including structural racism, language barriers, and provider shortages. The extent to which TBH diminishes or amplifies these specific barriers and reduces BH disparities is unknown. Recently, the COVID-19 pandemic accelerated policy changes to make telehealth services more widely available. However, state-level Medicaid policies are not uniform, and not all states retained pandemic- era expansions in their reimbursement policy. As policies influencing availability of telehealth continue to evolve, quantifying policy impacts on perinatal BH care access and outcomes, and better understanding the mechanisms driving those impacts, are critical to using TBH more effectively to address maternal morbidity and mortality from untreated perinatal BH conditions. To fill these gaps, this mixed-methods study will (1) Develop a detailed, longitudinal dataset describing the evolution of state-level telehealth policies with relevance to perinatal behavioral healthcare for individuals insured by Medicaid; (2) Use event-time modeling to estimate the relationship between telehealth policies of interest and key behavioral health outcomes (e.g., emergency department visits, overdoses, and suicide) and maternal-infant outcomes (e.g., maternal morbidity, preterm delivery), with a focus on identifying inequities by race/ethnicity, rural residence, and disability status; and (3) Apply the Consolidated Framework for Implementation Research in a series of in-depth interviews with patients and providers to explain the quantitative findings through an examination of factors that influence telehealth policy implementation and associated health outcomes.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "15253", "attributes": { "award_id": "1R21AR083058-01A1", "title": "Video Disease Activity Index: A novel video measure to monitor rheumatoid arthritis in telehealth", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)" ], "program_reference_codes": [], "program_officials": [ { "id": 26899, "first_name": "Su-Yau", "last_name": "Mao", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2024-08-20", "end_date": "2026-06-30", "award_amount": 202312, "principal_investigator": { "id": 31841, "first_name": "ROBERT D", "last_name": "HOWE", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 455, "ror": "https://ror.org/03vek6s52", "name": "Harvard University", "address": "", "city": "", "state": "MA", "zip": "", "country": "United States", "approved": true }, "abstract": "Title Video Disease Activity Index: a video measure to monitor rheumatoid arthritis in telemedicine Project Summary/Abstract Rheumatoid arthritis (RA) is a degenerative autoimmune condition of the joints that is treated with medications that suppress the immune system. Medications must be regularly adjusted according to disease activity, based on clinical examination. Telemedicine has gained a key role in rheumatology during the COVID-19 pandemic, with rheumatologists amending treatment based on patient reports of disease activity and signs of swelling observed on video. However, numerous studies have proven that telemedicine may miss critical information that affects how disease activity is treated. The proposed project aims to improve the accuracy of assessing disease activity and functioning in RA during telemedicine visits by using laptops and smartphone standard cameras. This will also help reduce the costs associated with objective evaluation for RA. The overall goal of this exploratory and developmental R21 project is to assess technical feasibility and patient usability of camera- based remote assessment system. The first aim is to develop a web-based system that leverages computer vision to quantify joint range of motion and joint thickness as an indication of joint swelling in RA to determine disease activity. We also aim to modify and improve the current method of assessing functional impairment by incorporating isometric grip strength using an in-house squeezable ball. During this first phase, the vision-based system and the squeezable ball will be validated on young and older adults through comparison with gold- standard techniques (e.g., motion capture). The second aim is to evaluate a new scoring system called the Video Disease Activity Index (VDAI) in a cross-sectional feasibility investigation with RA patients (n = 50). The VDAI scoring system will be produced by quantifying joint range of motion and joint thickness to determine the number of swollen joints. This will provide a measure of disease activity that aligns with the clinically endorsed Clinical Disease Activity Index (CDAI), which will be measured by a rheumatologist in the clinic. Two tests of the VDAI will be conducted: one with a researcher present to evaluate the system's sensitivity and reliability against clinical examination (CDAI), and another where RA patients will use the web-based application alone, while still in the clinic, with a vision-based feedback algorithm to perform the required activities. As the VDAI and CDAI are on the same scale (0–24), the study will use joint-level power calculations to permit standard limits of agreement analysis between the two measures (e.g., Bland-Altman). The correlation between grip strength and functional questionnaire scores will also be evaluated using Pearson's tests. These analyses will provide a robust evaluation of the sensitivity and reliability of the VDAI system and its potential to improve the accuracy of assessing disease activity and functioning in RA during telemedicine visits. By leveraging ubiquitous cameras, this investigation has the potential to significantly increase the quality of disease activity and functioning in RA during telemedicine visits.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "15254", "attributes": { "award_id": "1F31HL168966-01A1", "title": "Mechanisms of regenerative decline in aged alveolar type 2 cells", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Heart Lung and Blood Institute (NHLBI)" ], "program_reference_codes": [], "program_officials": [ { "id": 22589, "first_name": "CHRISTIAN RENE", "last_name": "Gomez", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2024-08-01", "end_date": "2026-07-31", "award_amount": 36138, "principal_investigator": { "id": 31842, "first_name": "Jake", "last_name": "Jensen", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 961, "ror": "", "name": "HARVARD SCHOOL OF PUBLIC HEALTH", "address": "", "city": "", "state": "MA", "zip": "", "country": "United States", "approved": true }, "abstract": "The delicate gas-exchange surface of the lung is the site of many burdensome diseases, including COVID-19- induced acute respiratory distress syndrome (ARDS), chronic obstructive pulmonary disease (COPD), and interstitial lung diseases (ILDs). Old age is a well-established predictor of the incidence and severity of these diseases. Alveolar type 2 (AT2) cells, which acts as the guardian of the gas exchange surface against injury and natural turnover via their progenitor cell activity, are detrimentally impacted by aging. AT2 cell self-renewal and differentiation to produce new alveolar type 1 (AT1) cells, the cells that exchange gas with the capillaries, is compromised in old age. In contrast, other progenitor cell populations in the airways of the lung show little evidence of age-related stem cell exhaustion. Why AT2 cell regenerative capacity is reduced in old age is still an open question. Our preliminary studies in mice supported by a single nuclear RNA and ATAC sequencing dataset demonstrated that old AT2 cells have an IFNγ-inducible transcriptional signature, a cytokine critical for many functions in innate and adaptive immunity. IFNγ is elevated in the aged mouse lung, and evidence exists that IFNγ represses AT2 cell growth in human alveolar organoids and mouse disease models. Resident and infiltrating lymphocytes, which act to surveil the lung epithelium for infectious cells, are often the main source of IFNγ during an immune response. Additional preliminary studies demonstrate that there is an enrichment of resident lymphocytes and resident natural killer cells in aged mouse lungs, indicative of more interactions and/or paracrine signaling within the aged lung parenchyma. It is not known whether elevated IFNγ and/or the changes in lymphocyte populations observed in the healthy aging lung influence AT2 cell regenerative decline. We hypothesize that resident natural killer cells contribute to elevated IFNγ in the aging lung which induces AT2 cell- specific regenerative decline. A variety of approaches will be taken to determine if elevated IFNγ or aging lymphocyte populations are 1) necessary for aging AT2 cell regenerative decline and 2) whether they are sufficient to block AT2 cell regeneration. In vivo alveolar injury from bleomycin, alveolar organoid forming assays, and BH3 profiling will be used to assess AT2 cell regenerative capacity and apoptotic potential. Additionally, flow cytometry and multiple imaging techniques, such as RNA in situ hybridization and immunofluorescent staining, will be used to quantitate and localize lymphocytes or cells releasing IFNγ in the aging lung. Using these strategies, this proposal will answer pertinent questions about shifts in aged AT2 cell-immune interactions, the origins of aging AT2 cell exhaustion, and the role of the aging microenvironment in the causation of age-related disease. This knowledge could prove crucial for proper preventative care and targeted therapies in individuals with age-related lung disease in the future.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "15255", "attributes": { "award_id": "1K99HL173656-01", "title": "Mesenchymal cell plasticity and signaling in lung regeneration", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Heart Lung and Blood Institute (NHLBI)" ], "program_reference_codes": [], "program_officials": [ { "id": 26342, "first_name": "MARISOL", "last_name": "Espinoza-Pintucci", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2024-08-01", "end_date": "2026-07-31", "award_amount": 156665, "principal_investigator": { "id": 31843, "first_name": "Dakota L", "last_name": "Jones", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 232, "ror": "https://ror.org/00b30xv10", "name": "University of Pennsylvania", "address": "", "city": "", "state": "PA", "zip": "", "country": "United States", "approved": true }, "abstract": "Regeneration of the lung following severe injury is an imperfect process and frequently leads to permanently altered lung structure and dysplastic cell types. After severe injury, such as influenza or COVID-19, the alveolus can either regenerate in form and function (adaptive regeneration) or be replaced by airway-derived dysplastic epithelium (maladaptive repair). These maladaptive cells and structures do not participate in gas exchange and likely contribute to the long-term reduction in pulmonary function seen in some patients from severe lung injury, highlighting the need for the development of new therapeutics with which to promote functional adaptive alveolar regeneration. Developing these new therapies will require a comprehensive understanding of not only the progenitor cells and their functions after injury, but also how they signal and interact with other cells within the injured alveolar niche. The alveolus is composed of a fragile layer of epithelium surrounded by a dense network of mesenchymal cells which serve important roles in paracrine signaling within the alveolar niche. Recent work from our lab and others has demonstrated the heterogeneity of these cells, identifying two key populations of alveolar mesenchyme, those that express Pdgfra (alpha+) and those that express Pdgfrb (beta+). Based on my extensive preliminary data demonstrating a key role of alpha+ cell proliferation, plasticity, and Notch signaling in alveolar regeneration after viral injury in both mouse and human lungs, I will test the hypothesize that specific mesenchymal cell lineages that arise from injury-induced plasticity establish and maintain the maladaptive epithelial regenerative response, in part through Notch mesenchymal-epithelial signaling. In Aim 1 of this proposal, I will examine how alpha+ cell proliferation and plasticity are defined and maintained after viral injury. The proposed research in Aim 1 will further develop my skills in transcriptomic and epigenomic analyses and physiological impacts of injury on lung function. In the independent phase outlined in Aim 2, I will define the importance of Notch mediated mesenchymal paracrine signaling within the alveolar niche during adaptive vs maladaptive regeneration. My primary mentor, Dr. Edward Morrisey is an internationally renowned lung biologist who has identified many key cell types and pathways which drive regeneration of the injured lung. I have also assembled a diverse advisory committee of experts in bioinformatics, epigenetics, physiologic readouts of recovery of lung function after injury, and Notch signaling who will assist me in training of these areas. The proposed work will be conducted at the University of Pennsylvania, where I will benefit from the rich intellectual environment, wide-ranging resources, collaborative scientific community in pulmonary and mesenchymal biology, and the full support of the institution. Together, this proposal outlines a rigorous research and training plan that will establish the foundation to advance my career in lung and mesenchymal cell biology.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "15755", "attributes": { "award_id": "4R00HL173656-03", "title": "Mesenchymal cell plasticity and signaling in lung regeneration", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Heart Lung and Blood Institute (NHLBI)" ], "program_reference_codes": [], "program_officials": [ { "id": 32818, "first_name": "MARISOL", "last_name": "ESPINOZA-PINTUCCI", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2025-08-04", "end_date": "2028-07-31", "award_amount": 248999, "principal_investigator": { "id": 31843, "first_name": "Dakota L", "last_name": "Jones", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 2625, "ror": "", "name": "UNIVERSITY OF IOWA", "address": "", "city": "", "state": "IA", "zip": "", "country": "United States", "approved": true }, "abstract": "Regeneration of the lung following severe injury is an imperfect process and frequently leads to permanently altered lung structure and dysplastic cell types. After severe injury, such as influenza or COVID-19, the alveolus can either regenerate in form and function (adaptive regeneration) or be replaced by airway-derived dysplastic epithelium (maladaptive repair). These maladaptive cells and structures do not participate in gas exchange and likely contribute to the long-term reduction in pulmonary function seen in some patients from severe lung injury, highlighting the need for the development of new therapeutics with which to promote functional adaptive alveolar regeneration. Developing these new therapies will require a comprehensive understanding of not only the progenitor cells and their functions after injury, but also how they signal and interact with other cells within the injured alveolar niche. The alveolus is composed of a fragile layer of epithelium surrounded by a dense network of mesenchymal cells which serve important roles in paracrine signaling within the alveolar niche. Recent work from our lab and others has demonstrated the heterogeneity of these cells, identifying two key populations of alveolar mesenchyme, those that express Pdgfra (alpha+) and those that express Pdgfrb (beta+). Based on my extensive preliminary data demonstrating a key role of alpha+ cell proliferation, plasticity, and Notch signaling in alveolar regeneration after viral injury in both mouse and human lungs, I will test the hypothesize that specific mesenchymal cell lineages that arise from injury-induced plasticity establish and maintain the maladaptive epithelial regenerative response, in part through Notch mesenchymal-epithelial signaling. In Aim 1 of this proposal, I will examine how alpha+ cell proliferation and plasticity are defined and maintained after viral injury. The proposed research in Aim 1 will further develop my skills in transcriptomic and epigenomic analyses and physiological impacts of injury on lung function. In the independent phase outlined in Aim 2, I will define the importance of Notch mediated mesenchymal paracrine signaling within the alveolar niche during adaptive vs maladaptive regeneration. My primary mentor, Dr. Edward Morrisey is an internationally renowned lung biologist who has identified many key cell types and pathways which drive regeneration of the injured lung. I have also assembled a diverse advisory committee of experts in bioinformatics, epigenetics, physiologic readouts of recovery of lung function after injury, and Notch signaling who will assist me in training of these areas. The proposed work will be conducted at the University of Pennsylvania, where I will benefit from the rich intellectual environment, wide-ranging resources, collaborative scientific community in pulmonary and mesenchymal biology, and the full support of the institution. Together, this proposal outlines a rigorous research and training plan that will establish the foundation to advance my career in lung and mesenchymal cell biology.", "keywords": [ "Advisory Committees", "Alpha Cell", "Alveolar", "Alveolus", "Area", "Beta Cell", "Bioinformatics", "Biological Assay", "Biology", "COVID-19", "COVID-19 patient", "Cell Differentiation process", "Cell Lineage", "Cell Physiology", "Cell Proliferation", "Cell division", "Cells", "Cellular biology", "Chronic", "Chronic lung disease", "Coculture Techniques", "Communities", "Confocal Microscopy", "Data", "Development", "Distal", "Environment", "Epigenetic Process", "Epithelial Cells", "Epithelium", "Equilibrium", "Exhibits", "Foundations", "Future", "Gases", "Genetic Transcription", "Genomics", "Heterogeneity", "Human", "Influenza", "Injury", "Institution", "International", "Intervention", "Label", "Lead", "Lentivirus", "Lineage Tracing", "Lung", "Lung infections", "Maintenance", "Mediating", "Mentors", "Mesenchymal", "Mesenchyme", "Modeling", "Mus", "NOTCH3 gene", "Natural regeneration", "Organoids", "Paracrine Communication", "Pathologic", "Pathology", "Pathway interactions", "Patients", "Pennsylvania", "Phase", "Physiological", "Population", "Positioning Attribute", "Process", "Proliferating", "Recovery", "Regenerative response", "Research", "Research Personnel", "Resources", "Role", "Signal Transduction", "Sorting", "Structure", "Testing", "Therapeutic", "Time", "Training", "Transgenic Mice", "Universities", "Viral", "Viral Respiratory Tract Infection", "Virus Diseases", "Work", "alveolar epithelium", "alveolar homeostasis", "career", "cell type", "epigenomics", "epithelium regeneration", "influenza infection", "injured", "insight", "keratinization", "lung injury", "lung regeneration", "multiple omics", "notch protein", "novel", "novel therapeutics", "post-doctoral training", "progenitor", "pulmonary", "pulmonary function", "receptor", "regeneration function", "regenerative", "repaired", "response", "severe injury", "single cell genomics", "single-cell RNA sequencing", "skills", "spatiotemporal", "stem cells", "transcriptomics" ], "approved": true } }, { "type": "Grant", "id": "15256", "attributes": { "award_id": "1R01AI179891-01", "title": "A Rapid Phenotypic Drug Susceptibility Testing System for Tuberculosis", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 7856, "first_name": "Karen A.", "last_name": "Lacourciere", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2024-08-23", "end_date": "2029-06-30", "award_amount": 610516, "principal_investigator": { "id": 31844, "first_name": "Mireille", "last_name": "Kamariza", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 818, "ror": "", "name": "UNIVERSITY OF CALIFORNIA LOS ANGELES", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true }, "abstract": "Tuberculosis (TB) is second only to COVID-19 as the most lethal cause of death from a single infectious agent. In 2020, an estimated 10 million people developed TB, nearly half a million of which were infected with drug- resistant tuberculosis (DR-TB). Early detection of infection and drug resistance is critical to controlling DR-TB as this enables rapid engagement into effective care. Unfortunately, only 71% of newly diagnosed TB patients are ever tested for rifampicin resistance, and even fewer receive more comprehensive testing. Additionally, despite improved treatment success rates for DR-TB globally, these success rates do not reflect upstream losses resulting from undiagnosed (missing cases) and untreated patients. Currently, bacterial culture and nucleic acid testing remain the primary methods for diagnosing infection, with smear microscopy being phased out. However, these methods present significant limitations for diagnosing drug resistance such as lengthy time-to-result for phenotypic tests, as well as the need for a priori knowledge of resistance mutations and prohibitive cost for molecular tests. Clearly, there remains a critical need for a fast, accurate, and cost-effective DST, particularly for resource-limited settings. To address this, we propose to design and develop a rapid phenotypic drug susceptibility test that can be easily adapted in TB endemic regions. The trehalose- based DST, termed Tre-DST, is based on novel trehalose probes, which require metabolic conversion to emit fluorescent signals, giving them their unique ability to specifically detect live Mycobacterium tuberculosis (Mtb). Agnostic to mechanism(s) of drug resistance, Tre-DST can be used with all WHO-recommended DRTB drugs, as well as any future TB drugs as a companion diagnostic. In Aim 1, we will develop, characterize, and optimize a family of novel fluorescent trehalose probes (3HC-Tre and RMR-Tre) that are specifically designed to improve performance over DMN-Tre and to distinguish live Mtb, making them ideal as biomarkers of drug susceptibility. We will also evaluate probe specificity to TB and probe performance across a variety of bacteria typically present in oral mucosa. In Aim 2, we will develop and optimize Tre-DST as a multi-drug DST for first- and second-line TB drugs. We will evaluate Tre-DST’s performance in accurately determining drug resistance using drug susceptible and drug resistant Mtb strains, treated singly and in combination with the anti- TB drugs that fulfill the WHO Target Product Profile (TPP) for next generation DST. We will also evaluate several point-of-care (POC)-friendly detection methods to optimize efficiency and cost-effectiveness. Lastly, in Aim 3, we will perform preliminary evaluation using banked clinical isolates in Johannesburg, South Africa to assess the performance of Tre-DST in the field. We will evaluate pre-validated readout methods in this clinical study, benchmarking the performance of Tre-DST against bacterial culture.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "15257", "attributes": { "award_id": "1R01AI179709-01A1", "title": "Immunogenetics of COVID-19 Immune Response", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 26918, "first_name": "Michelle Marie", "last_name": "Arnold", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2024-08-01", "end_date": "2029-07-31", "award_amount": 814873, "principal_investigator": { "id": 31845, "first_name": "Richard B", "last_name": "Kennedy", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 1426, "ror": "", "name": "MAYO CLINIC ROCHESTER", "address": "", "city": "", "state": "MN", "zip": "", "country": "United States", "approved": true }, "abstract": "This application is a request for funding of a vaccine immunogenetics research program focused on identifying critical genetic and phenotypic determinants of COVID-19 infection and/or vaccination-induced immunity by examining associations between gene polymorphisms, HLA allelic variation, and clinical phenotypes and inter- individual variations in immune response to COVID-19. Our laboratory has done significant work delineating the effect of gene polymorphisms on mumps, measles, rubella, influenza, and smallpox vaccine immune responses. Our research demonstrates that variations in immune responses to viral vaccines are multigenic and not a single dominant allele model and that the genetic contribution to such variations in immune responses can be quantified. Informed by insights from these studies and given the public health importance of the ongoing SARS-CoV-2 pandemic, we now turn our attention to understanding genetic associations with COVID-19-induced immune responses (regardless of whether they are vaccine or infection-induced, or a result of hybrid immunity). The most thorough and efficient study for such purposes is a comprehensive discovery/replication genome-wide association study (GWAS), to which we will add a phenome association study (PheWAS) followed by a more complete characterization of distinct immune effector mechanisms believed to contribute to protective immunity. Our studies will identify gene polymorphisms and pathways having the largest or most critical impact on inter-individual variations in immunity among subjects, and how comorbidities (phenotypes) contribute to these variations. Our Specific Aims are to 1) perform a large, genome-wide association study to identify novel genetic associations between SNPs and HLA alleles and inter-individual variations in the humoral immune response to COVID-19 infection or vaccination; identify polygenic risk scores predictive of antibody response; replicate the findings in an independent cohort; evaluate significant findings in a cohort with documented infection and no vaccination; 2) conduct a phenome-wide association study to quantify the effect of additional subject characteristics (e.g., age, sex, race, ethnicity, BMI), comorbidities, and phecodes (clusters of ICD10 codes) on the antibody response to COVID-19 vaccines; and 3) Evaluate the effect of genetic variation and host factors on T cell and B cell markers of immune response following vaccination. These aims will allow us to comprehensively define how inter-individual variations in immune responses to COVID-19 vaccine are influenced by gene polymorphisms and host characteristics. Notably, despite the public health implications, there are no population-based studies identifying associations between COVID-19 vaccine immune response and genome-wide SNPs or clinical phenotypes. Our study is carefully designed to be rigorous and produce robust, unbiased, and reproducible results applicable to the US population.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "15258", "attributes": { "award_id": "1R01MD019094-01A1", "title": "Modeling Health Equity and Economic Impacts of National Strategies to Address Food and Nutrition Insecurity", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute on Minority Health and Health Disparities (NIMHD)" ], "program_reference_codes": [], "program_officials": [ { "id": 31846, "first_name": "VANESSA J", "last_name": "Marshall", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2024-08-23", "end_date": "2028-02-28", "award_amount": 750910, "principal_investigator": { "id": 31847, "first_name": "David Daeho", "last_name": "Kim", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 289, "ror": "https://ror.org/024mw5h28", "name": "University of Chicago", "address": "", "city": "", "state": "IL", "zip": "", "country": "United States", "approved": true }, "abstract": "With worsening food insecurity in the COVID-19 pandemic and rising food prices, a 2022 White House initiative sought to address diet-related diseases (e.g., obesity, diabetes, cardiovascular disease) and disparities through food and nutrition insecurity interventions. However, Policymakers lack critical evidence on the effects of promising interventions to address food and nutrition insecurity because of no available evidence on long-term population health, effects on health disparities, and cost-effectiveness. This proposal seeks to fill these gaps by improving our understanding of the health equity and economic effects of different food and nutrition interventions and providing important evidence to support national priorities around diet-related diseases and health disparities. Based on three criteria: (a) strategies outlined in the 2022 White House report, (b) conceptual framework based on a health impact pyramid and NIMHD research framework regarding the domains of influence (population- vs. individual-based), and (c) availability of supporting evidence, we have identified four highly promising interventions to address food and nutrition insecurity: (1) expanding the USDA-supported Gus Schumacher Nutrition Incentive Program and (2) expanding the SNAP benefits and eligibility, (3) accelerating uptake of food/nutrition security screening and (4) enhancing access to nutrition/obesity counseling. Using our NIH-funded, validated, state-of-the-art, and dynamic microsimulation model, this project will measure the longer-term health outcomes, health equity, and economic impact of these four highly promising policy interventions to address food and nutrition insecurity on the US adult population and across racial/ethnic and socioeconomic groups. Through robust sensitivity and scenario analyses, our analytic framework allows us to examine the heterogeneous effects of these diverse interventions on long-term effectiveness and cost-effectiveness across population subgroups and whether such heterogeneous effects reflect differences in baseline risks (e.g., food insecurity) or vulnerability to the risk (e.g., effects of food insecurity on outcomes) or intervention’s effects across subgroups. Our innovative approach and multidisciplinary expert research team uniquely position us to measure long-term population health effects of food and nutrition insecurity interventions (Aim 1), estimate long-term effects on health disparity across population subgroups of food and nutrition insecurity interventions (Aim 2), quantify economic effects and cost- effectiveness of food and nutrition insecurity interventions (Aim 3). An independent dissemination aim will improve knowledge translation to end-users by conducting legal and administrative feasibility analysis and developing a web-based interactive platform (National Food and Nutrition Policy Impact Simulator). With the growing need for more robust evidence to address food and nutrition insecurity, our project will generate policy-relevant evidence on optimal policy choices that may depend on how different interventions affect long-term population health, certain key groups (i.e., reducing disparities), and overall cost-effectiveness. Using such evidence, policymakers can prioritize evidence-based national food and nutrition policies.", "keywords": [], "approved": true } } ], "meta": { "pagination": { "page": 1385, "pages": 1442, "count": 14420 } } }